Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)
- Status
- UNKNOWN
- Phase
- PHASE2
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE2
An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
- Status
- COMPLETED
- Phase
- PHASE1